Psyched Wellness Ltd · CSE:PSYC
Psyched Wellness — Investor Presentation (2021)
17 slides from Psyched Wellness's investor presentation, 2021
Slide 1: Corporate Deck
Corporate Deck CSE:PSYC OTCQB:PSYCF FRANKFURT:5U9
Slide 2: Forward Looking Statements
FORWARD LOOKING STATEMENTS This document and the material contained herein are confidential and are not to be disclosed to the public. This is for information purposes only and may not be reproduced or distributed to any other person or published, in whole or part, for any purpose whatsoever. Certai
Slide 3: At a glance
At a glance Psyched Wellness Ltd. is a Canadian-based Life Sciences company focused on the research and development of a legal psychedelic mushroom called Amanita Muscaria. Psyched Wellness is led by a strong team including experts in all key streams for an R&D public company and is currently engage
Slide 4: We are launching the first legal Amanita Muscaria mushroom product in North America
We are launching the first legal Amanita Muscaria mushroom product in North America. Our product is the only Amanita Muscaria product approved for sale as a food supplement in the USA. Calm harnesses the mushroom’s restorative powers to soothe the body, calm the mind, and tackle physical distress. P
Slide 5: Uncapped Retailer Landscape
Uncapped Retailer Landscape Unlike Psilocybin, our Amanita Muscaria Tincture with AME-1 will be available for sale at traditional retailers and without a prescription. This means Psyched Wellness has the potential to sell our product to over 232,202 relevant retail locations, in the US alone. With n
Slide 6: Investment Highlights
Investment Highlights: 1. First mover advantage as the only public 2. Expedited path to market/revenue as a company studying Amanita Muscaria food supplement via the FDA(a New Dietary Ingredient) and Health Canada (a Natural Health Product Number) 3. Management supported by top tier board 4. Global
Slide 7: White and Private Labelling Opportunities
White and Private Labelling Opportunities White labeling allows you to offer Amanita Muscaria products to your consumers with your branding. We plan to licence our proprietary extract, AME-1, to partner organizations for use in their own product innovation. This allows Psyched Wellness to open addit
Slide 8: Management Team
Management Team: Jeff Stevens David Shisel Matthew Singh Keith Li CEO & DIRECTOR COO CCO CFO Mr. Stevens has 20+ years of Mr. Shisel is an entrepreneur Mr. Singh is a seasoned Consumer Mr. Li is a CPA, CA with 10+ capital markets experience specializing in the medical Packaged Goods (CPG) executive
Slide 9: About Amanita Muscaria
About Amanita Muscaria: Iconic mushroom Ancient use Unique compounds Not poisonous Amanita Muscaria typifies the Amanita Muscaria has been The major compounds, ibotenic This mushroom has been iconic image of psychogenic and consumed by cultures acid and muscimol, are water- mislabelled as poisonous.
Slide 10: Achievements
Achievements Psyched Wellness has achieved many milestones, such as becoming the first public company to complete pre-clinical studies with a licensed CRO partner focused on Amanita Muscaria. Our go-to-market strategy includes Self-Gras (generally regarded as safe) status in the USA within the first
Slide 11: Product Development & Marketing Rollout
Product Development & Marketing Rollout Q1 2022 Q2 2022 Q3 2022 Q4 2022 • Launch a new website (desktop and • GRAS approval for the USA • Commence R&D on Psyched Wellness’s • The FDA approves Psyched mobile) • Host a digital summit to introduce the sleep aid tea - AME-1 Wellness’s AME-1 as a NDI • S
Slide 12: 2022 Action Plan
2022 Action Plan • Psyched Wellness will finalize its R&D process and will start sales of its first flagship Amanita Muscaria tincture in the USA as a New Dietary Ingredient (NDI) and will apply to sell it in Canada as a Natural Health Product (NHP). • This will be the first psychedelic food supplem
Slide 13: Capital Structure
Capital Structure Currently Issued and Outstanding Common Shares* 130,589,695 Finders Warrants 24,806,365 Options 12,875,000 Fully Diluted Issued and Outstanding 177,571,060 *Psyched announced a bought deal financing on January 22, 2021. The deal was upsized from $3M to $5.5M dollars plus the over-a
Slide 14: Board of Directors
Board of Directors Michael Nederhoff Terry Booth Professor David Nutt CHAIRMAN DIRECTOR DIRECTOR Currently acts as President of JUUL Labs in Global cannabis industry pioneer and David Nutt is a psychiatrist and the Edmond J. Canada overseeing Canadian operations founder of Aurora Cannabis (TSX-ACB).
Slide 15: Board of Directors (cont'd)
Board of Directors (cont'd) Nick Kadysh Janeen Stodulski Amanda Galbraith DIRECTOR DIRECTOR DIRECTOR Head of Corporate Affairs at UUL MA graduate of Brock University, Janeen received her CPA Amanda Galbraith is one of Canada’s foremost crisis Labs Canada. Formerly served as designation in 1999 and h
Slide 16: Advisory Board
Advisory Board Dr. Dawn DeCunha Dr. Andrew Kohler Brian Tancowny ADVISOR ADVISOR ADVISOR Dr. Dawn DeCunha is a clinical psychologist, with Dr. Kohler is the founder and owner of Callingwood Mr. Brian Tancowny has over 25 years of experience in an active practice in Toronto, Canada. She is a Crossing
Slide 17: Contact
Contact Address 77 King St West Toronto, ON, Canada M5K 1G8 Jeff Stevens CEO & Director jstevens@psyched-wellness.com (647) 400-8494 Investor Contact: Tim Regan & Sophia Bashford KCSA Strategic Communications (978) 505-2478 psychedwellness@kcsa.com